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To the pyrazoline 2 (0.001M) in pyridine (10mL), benzoyl chloride (0.002M) was added. The reaction mixture was heated on water bath for 3-4 h and poured over crushed ice mixed with dilute hydrochloric acid. The solid separated out was filtered, washed with water, dried and recrystallized from ethanol to afford desired compound. Yield: 85%; mp: 50-53 ºC; [α] 30.5 =-5.51°; 
Synthetic procedure for the synthesis of 4-(5-(4-chlorophenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxyphenol (4)
1 p-Toluene sulphonyl chloride (0.0025) was dissolved in tetrahydrofuran (2 mL) with stirring. The stirred mixture was cooled in an ice bath to 10-15 o C; followed by gradual addition of a solution of pyrazoine2 in tetrahydrofuran so that the temperature was maintained between 10-15 o C. Stirring was continued for 10-15 min. after the addition was complete. The solid separated out was filtered, dried and recrystallized from methanol to afford desired compound. To the stirred solution of pyrazoine 2 (0.001M.) in absolute ethanol, was added phenyl isothiocyanate (0.002M.) and refluxed for 2-3 h. The obtained crude precipitate of product was filtered, washed with petroleum ether, dried, and was recrystallized from methanol. 
Specific rotation:
Compounds 2-6, in 5 mg quantity were dissolved in HPLC grade methanol. Sample solutions were then measured for specific rotation at  589 nm (sodium D line) using sample cell having 10 cm pathlength.
Chiral separation using analytical chiral column:
Chiral separation of the compounds were achieved using analytical chiral column CHIRALPAK 1 A (250 x 4.4 mm, 5 µ) with sample injection volume of 20 µL, mobile phase (5-10% isopropyl alcohol in n-hexane) flow rate of 1.0 mL/min. Detection was done at  210 nm. The data obtained is presented in Table S1 . 2. Biochemistry MAO activity screening: All the compounds were screened for their hMAO inhibitory activity using Amplex®-Red MAO assay Recombinant enzymes and chemicals were according to the manufacturer's instructions. The assay is a one-step fluorometric method for the continuous measurement of MAO activity using a fluorescence microplate reader. The assay is based on the detection of H 2 O 2 in a horseradish peroxidase coupled reaction using Amplex Red reagent, a highly sensitive and stable probe for H 2 O 2 . The reaction product, resorufin, is highly stable. No interference from autofluorescence was detected in the biological samples in our studies since resorufin has absorption and fluorescence emission maxima of 571 nm and 585 nm. p-tyramine (0.05-0.50 mM) was used as the common substrate for both hMAO-A and -B. Specific inhibitors of hMAO-A and -B were used for the determination of these hMAO isoforms.
Recombinant enzymes were diluted in a reaction buffer (containing 0.25 M of sodium phosphate, pH 7.4). 100 µL enzyme solution was used for each reaction. One of the MAO-inhibitors was included, by adding the equivalent of 0.2 µL of the 0.5 mM inhibitor stock solution (clorgyline or pargyline) to each 100 µL volume of diluted sample and the samples were preincubated at room temperature for 30 min. Enzyme and inhibitor concentrations were kept as two-fold lower in the final reaction volume. The positive control solution was prepared by diluting the 20 mM H 2 O 2 working solution to the final concentration of 10 µM in reaction buffer whereas the action buffer without H 2 O 2 was prepared as the negative control.
Reaction was started by adding 100 µL of the Amplex Red reagent (400 /HRP/substrate working solution) to each microplate well containing the samples and controls. Mixtures were incubated for 30 min at room temperature. Fluorescence was measured using excitation at 530 nm and emission at 590 nm at multiple time points to follow the kinetics of the reactions. Background fluorescence was corrected by subtracting the values derived from then o-amine oxidase control. The possible capacity of the new compounds to modify the fluorescence generated in the reaction mixture due to non-enzymatic inhibition was determined by adding these compounds to solutions containing only the Amplex Red reagent in a sodium phosphate buffer. Newly synthesized compounds did not cause any inhibition on the activity of HRP in the test medium.
Specific enzyme activities were calculated as 0.151 ± 0.007 nmol/mg/min (n=3) for hMAO-A and 0.133 ± 0.009 nmol/mg/min (n=3) for hMAO-B.
Kinetic studies
Synthesized compounds were dissolved in dimethyl sulfoxide (DMSO), with a maximum concentration of 1% and used in a concentration range of 0.01 µM-6.00 mM. Selegiline, moclobemide and lazabemide were dissolved also in DMSO in a concentration range of 0.01 µM-10 mM. The mode of hMAO inhibition was examined using Lineweaver-Burk plotting (refer to Figure 2 in Manuscript). The slopes of the Lineweaver-Burk plots were plotted versus the inhibitor concentration and the inhibitor constant (Ki) values were determined from the x-axis intercept as -Ki. Each Ki value is the representative of single determination where the correlation coefficient (R 2 ) of the replot of the slopes versus the inhibitor concentrations was at least 0.98. SI was calculated as Ki(hMAO-B)/Ki(hMAO-A). The protein was determined according to the Bradford method. 4 
Reversibility
Reversibility of the hMAO inhibition with the compounds was determined by dialysis method previously described. 5 Briefly, dialysis tubing of 16x25 mm with a molecular weight cut-off of 12,000 and a sample capacity of 0.5-10 mL was used. Recombinant enzymes were incubated with the compounds a concentration as fivefold of the K i values for the inhibition of hMAO-A and -B, respectively in potassium phosphate buffer (0.05 M, pH 7.4, 5% sucrose containing 1% DMSO) for 15 min. at 37 ºC. Other sets were prepared by preincubation of same amount of hMAO-A and -B with the reference inhibitors. Enzymeinhibitor mixtures were subsequently dialyzed at 4°C in dialysis buffer (100 mM potassium phosphate, pH 7.4, 5% sucrose). The dialysis was repeated two times during the 24 h of dialysis. After dialysis, residual MAO activities were measured (p-tyramine was used as substrate at 0.10 mM). All reactions were carried out in triplicate and the residual enzyme activity was expressed as mean±SEM (Table S2 ). For comparison, undialyzed mixtures of the MAOs and the inhibitors were included in the study. 
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Cytotoxicity Studies
Cell viability was measured by a quantitative colorimetric assay with 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) (Sigma Aldrich). 6 Human hepatoma cell line HepG2 (Invitrogen) was cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 2 mM L-Glutamine, 10% heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin. Cells were seeded in supplemented medium and maintained at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. Exponentially growing HepG2 cells were subcultured in 96-well plates. The cells were treated with the compounds at the concentrations of 1, 5 and 25 µM, and 0.1% DMSO as a vehicle control for 24 h. 10 µL of the MTT labeling reagent, at a final concentration of 5 mg/mL, was added to each well at the end of the incubation time and the plate placed in a humidified incubator at 37°C with 5% CO 2 and 95% air (v/v) for 4 h until the appearence of purple formazan crystals formed. Then, the insoluble formazan was dissolved with 100 µL of dimethylsulfoxide (DMSO) by shaking 1 h in darkness. MTT reduction was measured at 590 nm. Control cells treated with 0.1% DMSO were used as 100% viability. 7 Significance was determined using student's t-test. Results were expressed as mean±SEM. Differences are considered statistically significant at p<0.05.
In vitro blood-brain barrier permeation assay (PAMPA-BBB):
The penetration of newly synthesized compounds into brain was determined using parallel artificial membrane permeation assay (PAMPA) for blood-brain-barrier according to a previous method. 8 Briefly, compounds and the commercial drugs were dissolved in DMSO at a concentration of 5 mg/mL. They were diluted with a mixture of PBS/EtOH (70:30) to give a final concentration of 25 µg/mL. The filter membrane in donor microplate was coated with porcine polar brain lipid (PBL) dissolved in dodecane (4 µL, 20 mg/mL). 200 µL of diluted solution and 300 µL of PBS/EtOH (70:30) were added to the donor and the acceptor wells, respectively. The donor filter plate was carefully placed on the acceptor plate. Sandwich system was kept at 250 C for 16 h. The donor plate was carefully removed, and the concentrations of the compounds and the commercial drugs in the acceptor, donor and reference wells were measured with a UV plate reader.
Molecular modeling simulation
Molecular Docking Simulation Protocol.
Docking studies were performed using the AutoDock4.2 program, which combines the Lamarckian Genetic Algorithm with an empirical force field to yield fast predictions of binding modes and energies. Relative errors of 2-3 kcal/mol are typical per conformation. Determining the correct binding site of human monoamine oxidase A (hMAO-A) co-crystalized with harmine (HRM) [PDB ID: 2Z5X] was the initial priority.
9 AutoGridFR (AGFR) was used to compute the binding affinity over the entire receptor by scoring different binding pockets based on AutoSite (AS) results. 10 The AS score for the HRM binding site (colored in green in Figure S1 ) yielded the most favorable result. Interestingly, two additional regions, shown colored in orange and yellow in Figure S1 , were found adjacent to the flavin adenine dinucleotide (FAD) binding site that gave comparable AS scores. In order to cross check the predicted binding pockets, a separate program AutoLigand was used to calculate the binding affinity values at the HRM receptor site and to independently evaluate the alternative binding pockets. 11 Default protocol affinity maps were calculated for the receptor with grid size of 40 Å along the x, y and z axis with the grid centered on the receptor. Autoligand also predicted the highest binding affinity to be located at co-crystalized HRM site ( Figure S2) . Thus, the calculations suggest that any de novo designed ligands should target the HRM binding site.
Based on results from AGFR and AutoLigand, a grid was centered over the HRM binding region with a box size set at x = y = z = 30 grid points. Protein preparation was carried out by removing all crystallographic water molecules, adding polar hydrogens, computing Kollman charges, and assigning atomic radii and AutoDock4 atomtypes. Docking parameters were created using default values except the exhaustiveness of the global search was set to 100 and docking parameters were saved in DPF format. The co-crystalized HRM ligand was removed and re-docked using the prescribed method above and the binding mode was accurately reproduced ( Figure S3 ). After validating the docking method, the 2R, 2S, 4*R and 4*S were docked. The docking poses obtained for the 2R and 2S conformers had similar orientations compared to HRM in the receptor site. For example, the keto groups of R, S, and HRM compounds were oriented in same general direction within the active site ( Figure S4 ). Complexes of all the four ligands with hMAO-A were prepared for further molecular dynamics simulations. 
